PPARγ, a secondary activator of lipogenic gene expression in the liver [51], and targeted deletion of PPARγ in hepatocytes attenuated HFD-induced hepatic steatosis and upregulation of SREBP-1c [52]. Here, SREBF1 is linked to fatty liver disease.